Effect of the ABCB1 3435C>T polymorphism on tacrolimus concentrations and dosage requirements in liver transplant recipients

American Journal of Health-System Pharmacy

Volumn 66, Issue 18, 2009, Pages 1645-1651

  Bonhomme Faivre, Laurence ^a,b   Picard, Véronique ^c   Saliba, Faouzi ^d   Abbara, Chadi ^e   Fodil, Madjid ^e   Chaunoy, Mélanie ^f   Farinotti, Robert ^c  

^a HÔPITAL PAUL BROUSSE   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c AU

^d Hepato biliary Center   (France)

^e Pharmacy Pharmacology Service

^f HPB

Author keywords

Blood levels; Dosage; Immunosuppressive agents; Mycophenolate mofetil; Pharmacokinetics; Polymorphisms; Steroids, cortico; Tacrolimus; Transplantation

Indexed keywords

CORTICOSTEROID; GLYCOPROTEIN P; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ALLELE; ARTICLE; CADAVER DONOR; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; EXON; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 70349304415     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080396     Document Type: Article

References (36)

1. Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev. 1997; 27:201-214
2. Foote CJ, Greer W, Kiberd B et al. Polymorphisms of multidrug resistance gene (MDR1) and cyclosporine absorption in de novo renal transplant patients. Transplantation. 2007; 83:1380-1384 (Pubitemid 46800316)
3. Saeki T, Ueda K, Tanigawara Y et al. Human P-glycoprotein transports cyclosporin A and FK 506. J Biol Chem. 1993; 268:6077-6080 (Pubitemid 23099291)
4. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med. 2003; 348:538-549
5. Gonschior A, Christians U, Braun F et al. Measurement of blood concentrations of FK 506 (tacrolimus) and its metabolites in seven liver graft patients after first dose by HPLC-MS and microparticulate enzyme immunoassay (MEIA). Br J Clin Pharmacol. 1994; 38:567-571 (Pubitemid 24365865)
6. Jusko WJ, Piekoszewski W, Klintmalm GB et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther. 1995; 57:281-290
7. Böttiger Y, Undre NA, Säwe J et al. Effect of bile flow on the absorption of tacrolimus in liver allograft transplantation. Transplant Proc. 2002; 34:1544-1555 (Pubitemid 34895224)
8. Undre NA, van Hooff J, Christiaans M et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc. 1999; 31:296-298
9. Masuda S, Goto M, Fukatsu S et al. Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients. Clin Pharmacol Ther. 2006; 79:90-102. (Pubitemid 43069581)
10. Hoffmeyer S, Burk O, Von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 2000; 97:3473-3478 (Pubitemid 30183327)
11. Li D, Lu W, Zhu JY et al. Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients. J Clin Pharm Ther. 2007; 32:505-15. (Pubitemid 47404287)
12. Fukudo M, Yano I, Yoshimura A et al. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics. 2008; 18:413-423
13. Goto M, Masuda S, Kiuchi T et al. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics. 2004; 14:471-478 (Pubitemid 38971237)
14. Goto M, Masuda S, Saito H et al. 3435C>T polymorphism in the gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics. 2002; 12:451-457 (Pubitemid 34913527)
15. Wei-lin W, Jing J, Shu-sen Z et al. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transpl. 2006; 12:775-780
16. Demetris A, Adams D, Bellamy C et al. Update of the international Banff schema for liver allograft rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An international panel. Hepatology. 2000; 31:792-799
17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16:31-41.
18. Mourad M, Wallemacq P, De Meyer M et al. Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome. Transplantation. 2008; 85(suppl 7):S19-24.
19. Bernal ML, Sinues B, Fanlo A et al. Frequency distribution of 3435C>T mutation in exon 26 of the gene in a Spanish population. Ther Drug Monit. 2003; 25:107-111
20. Bonhomme-Faivre L, Devocelle A, Saliba F et al. MDR1 3435C>T polymorphism influences cyclosporin A dose requirement in liver-transplant recipients. Transplantation. 2004; 78:21-25
21. Thorn M, Lundgren S, Herlenius G et al. Gene expression of cytochromes P450 in liver transplants over time. Eur J Clin Pharmacol. 2004; 60:413-420 (Pubitemid 39214895)
22. Elens L, Capron A, Kerckhove VV et al. 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. Pharmacogenet Genomics. 2007; 17:873-883 (Pubitemid 47462301)
23. Lemahieu WP, Maes BD, Verbeke K et al. CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporine vs. tacrolimus vs. sirolimus. Am J Transplant. 2004; 4:1514-1522 (Pubitemid 39159067)
24. Lemahieu WP, Hermann M, Asberg A et al. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transplant. 2005; 5:2236-2243
25. Zheng HX, Schuetz E, Zeevi A et al. Sequential analysis of tacrolimus dosing in adult lung transplant patients with ABCB1 haplotypes. J Clin Pharmacol. 2005; 45:404-410 (Pubitemid 40490413)
26. Watchko JF, Daood MJ, Hansen TW. Brain bilirubin content in P-glycoprotein-deficient transgenic null mutant mice. Pediatr Res. 1998; 44:763-766
27. Watchko JF, Daood MJ, Mahmood B et al. P-glycoprotein and bilirubin disposition. J Perinatol. 2001; 21(suppl 1):S43-7.
28. Jacobson P, Ng J, Ratanatharathorn V et al. Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients. Bone Marrow Transplant. 2001; 28:753-758
29. Cohen AJ, Stegall MD, Rosen CB et al. Chronic renal dysfunction late after liver transplantation. Liver Transpl. 2002; 8:916-921 (Pubitemid 35154021)
30. Hebert MF, Dowling AL, Gierwatowski C et al. Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics. 2003; 13:661-674 (Pubitemid 38316510)
31. Macphee IA, Fredericks S, Tai T et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation. 2002; 74:1486-1489 (Pubitemid 36014218)
32. Akbas SH, Bilgen T, Keser I et al. The effect of (ABCB1) polymorphism on the pharmacokinetics of tacrolimus in Turkish renal transplant recipients. Transpl Proc. 2006; 38:1290-1292 (Pubitemid 43912729)
33. Anglicheau D, Verstuyft C, Puig PL et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol. 2003; 14:1889-1896 (Pubitemid 36750485)
34. Fredericks S, Moreton M, Reboux S et al. Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. Transplantation. 2006; 82:705-708 (Pubitemid 44395243)
35. Masuda S, Goto M, Okuda M et al. Initial dosage adjustment for oral administration of tacrolimus using the intestinal level in living-donor liver transplant recipients. Transpl Proc. 2005; 37:1728-1729 (Pubitemid 40790811)
36. Sakaeda T, Nakamura T, Horinouchi M et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res. 2001; 18:1400-1404 (Pubitemid 32977244)